Literature DB >> 12412783

Primary hyperparathyroidism and the kidney: biochemical and clinical spectrum.

Munro Peacock1.   

Abstract

Primary hyperparathyroidism manifests biochemically as a disturbance in serum calcium homeostasis. The central organ setting serum calcium level is the kidney. It not only has the highest rate of active calcium transport, but the kidney also modulates serum calcium homeostasis by virtue of its endocrine role in 1,25-hydroxyvitamin D secretion. Receptors for PTH are widely expressed throughout the renal tubule and are involved in both calcium transport and endocrine function. Biochemical manifestations of primary hyperparathyroidism by the kidney include increased tubular reabsorption of calcium, decreased reabsorption of phosphate and bicarbonate, and hypercalciuria. A reduction in glomerular filtration may occur in some patients with primary hyperparathyroidism, which perturbs the diagnostic relationships among biochemical variables and induces further increases in PTH secretion. Parathyroidectomy rapidly restores the biochemical abnormalities to normal apart from chronic reduced glomerular filtration. Clinical manifestations are nephrolithiasis, which is common, and nephrocalcinosis, which is uncommon. Nephrocalcinosis may occur with or without nephrolithiasis. Risk factors for nephrolithiasis are oversaturation of urine with calcium phosphate and with calcium oxalate. Risk factors for nephrocalcinosis are not clearly defined. Parathyroidectomy greatly reduces the incidence of nephrolithiasis but has little effect on nephrocalcinosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12412783

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  15 in total

1.  Distal renal tubular acidosis in primary hyperparathyroidism.

Authors:  Tom Edward Ngo Lo; Iris Thiele Isip Tan
Journal:  BMJ Case Rep       Date:  2015-01-29

2.  Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.

Authors:  Peter L Havens; Charles B Stephensen; Rohan Hazra; Patricia M Flynn; Craig M Wilson; Brandy Rutledge; James Bethel; Cynthia G Pan; Leslie R Woodhouse; Marta D Van Loan; Nancy Liu; Jorge Lujan-Zilbermann; Alyne Baker; Bill G Kapogiannis; Kathleen Mulligan
Journal:  Clin Infect Dis       Date:  2012-01-19       Impact factor: 9.079

3.  A curious case of growth failure and hypercalcemia: Answers.

Authors:  Mallory L Downie; Jaap Mulder; Rayfel Schneider; Lillian Lim; Nasrin Tehrani; Jonathan D Wasserman; Shai Fuchs; Rohan John; Damien G Noone; Diane Hebert
Journal:  Pediatr Nephrol       Date:  2017-08-07       Impact factor: 3.714

4.  Effect of renal function on skeletal health in primary hyperparathyroidism.

Authors:  Marcella D Walker; David W Dempster; Donald J McMahon; Julia Udesky; Elizabeth Shane; John P Bilezikian; Shonni J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2012-03-07       Impact factor: 5.958

5.  Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?

Authors:  Peter L Havens; Jennifer J Kiser; Charles B Stephensen; Rohan Hazra; Patricia M Flynn; Craig M Wilson; Brandy Rutledge; James Bethel; Cynthia G Pan; Leslie R Woodhouse; Marta D Van Loan; Nancy Liu; Jorge Lujan-Zilbermann; Alyne Baker; Bill G Kapogiannis; Catherine M Gordon; Kathleen Mulligan
Journal:  Antimicrob Agents Chemother       Date:  2013-09-03       Impact factor: 5.191

6.  Primary hyperparathyroidism in Taiwan: clinical features and prevalence in a single-center experience.

Authors:  Han-Hsiang Chen; Yu-Wei Chen; Chih-Jen Wu
Journal:  Endocrine       Date:  2010-03-09       Impact factor: 3.633

7.  Approach to the Adult Kidney Stone Former.

Authors:  Naim Maalouf
Journal:  Clin Rev Bone Miner Metab       Date:  2012-03

8.  Predictors of renal function in primary hyperparathyroidism.

Authors:  Marcella D Walker; Thomas Nickolas; Anna Kepley; James A Lee; Chiyuan Zhang; Donald J McMahon; Shonni J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2014-02-14       Impact factor: 5.958

9.  Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop.

Authors:  Shonni J Silverberg; Bart L Clarke; Munro Peacock; Francisco Bandeira; Stephanie Boutroy; Natalie E Cusano; David Dempster; E Michael Lewiecki; Jian-Min Liu; Salvatore Minisola; Lars Rejnmark; Barbara C Silva; Marcella D Walker; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2014-08-27       Impact factor: 5.958

10.  Asymptomatic primary hyperparathyroidism: a commentary on the revised guidelines.

Authors:  Aliya A Khan; John P Bilezikian; John T Potts
Journal:  Endocr Pract       Date:  2009 Jul-Aug       Impact factor: 3.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.